Skip to main content
. Author manuscript; available in PMC: 2020 Mar 23.
Published in final edited form as: Melanoma Res. 2019 Oct;29(5):491–500. doi: 10.1097/CMR.0000000000000623

Figure 6: NRAS Isoform expression alters response to vemurafenib treatment.

Figure 6:

(A) Proliferation of NRAS isoform over-expressing cell lines in the presence of vemurafenib doses from 0–20 μM was measured by MTS assay after 48 hours of drug exposure, displayed as mean ± s.e.m of three replicate experiments. (B) Proportion of NRAS isoforms in BRAF/NRAS-mutant vs. wild-type (wt) metastatic melanoma patient tumors. The top and bottom quartile of NRAS isoform mRNA expression (RNAseq TCGA data in transcripts per million (TPM)). P values were determined via Fisher’s exact test.